Advances in PCR Technology and Its Applications in Healthcare Research
Breaking Through Barriers between Benchtop and Bedside
Cannibalism: A Biological and Evolutionary Perspective
Sounds of Science Podcast
Ubiquitin System: The Next Class of Drug Targets?
A Complex Role in Cellular Process & Growing Tool Set to Elucidate It
Bispecific Antibodies Close in on Cancer
Plotting Molecular Pincer Movements, Denying Cancer Room to Maneuver
U.K. Biotech Strategy
Intent on shepherding more biopharma companies to market and keeping them growing, Prime Minister David Cameron recently unveiled a “Strategy for UK Life Sciences”. The strategy calls for the U.K. to launch a £180 million ($278.6 million) fund to push startup companies past the “valley of death,” a £130 million ($201.2 million) personalized medicine research fund, and a £50 million ($77.4 million) cell therapy technology center, among other components. The strategy also promises a new initiative to speed up approvals of new drugs. “We must ensure that the U.K. stays ahead,” Cameron said. Do you think the Strategy will help the U.K. reach its goals for biotechnology?